RVMD Overview

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is86.00 USD with a low forecast of 67.00 USD and a high forecast of 147.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Revolution Medicines Inc revenue for the last quarter amounts to 0.00 USD, decreased

Revolution Medicines Inc. EPS for the last quarter amounts to -2.29 USD, increased 102.65

Revolution Medicines Inc (RVMD) has 883 emplpoyees as of May 18 2026.

Today RVMD has the market capitalization of 30.97B USD.